Multiple myeloma is a cancer that forms in a type of white blood cell that is called a plasma cell. Plasma cells help to fight infections by making antibodies. Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. Rather than produce helpful antibodies, the cancer cells produce abnormal proteins that can cause complications. For people with multiple myeloma who require treatment, a number of treatments are available to help control the disease.
Scope of the Report:
This report focuses on the Multiple Myeloma Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Cancer cells have higher levels of proteasome activity are more sensitive to the proapoptotic effects of proteasome inhibition than normal cells, which makes the proteasome a therapeutic target in multiple myeloma. Prot ...
Table of Contents
1 Market Overview
1.1 Multiple Myeloma Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Immunomodulatory drugs (IMiDs)
1.2.2 Proteasome inhibitors
1.2.4 Histone deacetylase inhibitor (HDAC inhibitor)
1.2.5 Steroids (corticosteroids)
1.3 Market Analysis by Applications
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
188.8.131.52 United States Market States and Outlook (2013-2023)
184.108.40.206 Canada Market States and Outlook (2013-2023)
220.127.116.11 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
18.104.22.168 Germany Market States and Outlook (2013-2023)
22.214.171.124 France Market States and Outlook (2013-2023)
126.96.36.199 UK Market States and Outlook (2013-2023)
188.8.131.52 Russia Market States and O ...